Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease

36Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Diabetic kidney disease (DKD) is the most common diabetic complication and is a leading cause of end-stage kidney disease. Increasing evidence shows that DKD is regulated not only by many classical signaling pathways but also by epigenetic mechanisms involving chromatin histone modifications, DNA methylation, and non-coding RNA (ncRNAs). In this review, we focus on our current understanding of the role and mechanisms of ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in the pathogenesis of DKD. Of them, the regulatory role of TGF-β/Smad3-dependent miRNAs and lncRNAs in DKD is highlighted. Importantly, miRNAs and lncRNAs as biomarkers and therapeutic targets for DKD are also described, and the perspective of ncRNAs as a novel therapeutic approach for combating diabetic nephropathy is also discussed.

Cite

CITATION STYLE

APA

Gu, Y. Y., Lu, F. H., Huang, X. R., Zhang, L., Mao, W., Yu, X. Q., … Lan, H. Y. (2021, January 26). Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. Frontiers in Pharmacology. Frontiers Media S.A. https://doi.org/10.3389/fphar.2020.583528

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free